XGene Regulatory Intelligence Platform
Connect enforcement signals to quality systems, services, expert commentary, and implementation resources.
The most expensive CMC failures in biologic drug development are not failed experiments — they are timeline surprises: discovering at the BLA assembly stage that the Phase 3 manufacturing process was not locked before
View details →
FAIR data principles — Findable, Accessible, Interoperable, and Reusable — are being adopted across pharmaceutical research and development, but their application to pharmaceutical CMC data has specific implications that go beyond the scientific data
View details → A bispecific antibody with two distinct antigen-binding domains, an Fc region for half-life extension, and an asymmetric format that generates multiple structural variants including mismatched half-antibodies is not a monoclonal antibody with extra binding
View details → TransCelerate BioPharma's pre-competitive collaboration model is the most instructive cross-industry precedent for how pharmaceutical regulatory data standards actually get built and adopted — and the structured CMC data standardization effort now underway through the
View details → Anti-drug antibody (ADA) responses to biologic therapeutics represent one of the most significant safety and efficacy risks in the therapeutic protein field — and the CMC quality attributes that predict ADA risk are measurable,
View details →
"When FDA enters a consent decree with a pharmaceutical manufacturer, it is not the end of an enforcement story — it is the most detailed public account FDA will ever provide of exactly what
View details →
A bispecific antibody is not two monoclonal antibodies sharing one Module 3. It is a single drug substance whose Module 3 characterization package must account for a manufacturing reality that standard IgG production doesn't
View details → CDISC standards — the Clinical Data Interchange Standards Consortium — are well established in clinical trial data management, but their intersection with pharmaceutical CMC is less understood and increasingly relevant as FDA and EMA
View details → A protein drug formulation development package that runs one pH condition, one temperature, and calls the stability program complete is not a formulation development package — it is a stability confirmation exercise wearing the
View details → Every pharmaceutical company that has committed to FAIR data principles has a beautiful diagram showing how their CMC data will be Findable, Accessible, Interoperable, and Reusable — and most of them discover during implementation
View details → A high-concentration antibody formulation isn't a standard mAb formulation scaled up in concentration — above roughly 100 mg/mL, viscosity becomes a manufacturability and deliverability constraint in its own right, not a formulation footnote. An
View details → The manual, document-centric process of assembling a CMC regulatory submission — exporting data from LIMS, pasting it into Word tables, formatting it for eCTD, and cross-referencing it across Module 3 sections — is being
View details → "Viral clearance data from scaled-down studies have not been provided for two of the chromatography steps — please provide the validation data or a scientific justification for omission." This deficiency, common in BLA CMC
View details → "When FDA convenes an advisory committee to examine how it evaluates CMC packages, it is signaling the direction of reviewer expectations before those expectations appear in final guidance — and the companies that read
View details → FDA's 2022 Computer Software Assurance guidance is not a minor update to the IQ/OQ/PQ validation framework — it is a conceptual redesign of how pharmaceutical companies should approach GMP software compliance, and organizations that
View details → The Annual Product Review — or Product Quality Review as EU GMP calls it — is one of the most universally produced and most universally underutilized documents in pharmaceutical manufacturing, and the companies that
View details →
The COVID-19 mRNA vaccine programs created a widespread assumption that the CMC framework developed for mRNA vaccines applies directly to mRNA therapeutics. It does not — not entirely — and understanding the differences is
View details → When FDA issues a 483 observation for inadequate control of materials, the citation almost always traces back to a supplier qualification program that checked a box rather than built a quality system — a
View details →